CAS 290815-26-8|Avosentan

Introduction：Basic information about CAS 290815-26-8|Avosentan, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Avosentan BiologicalActivity
3. Chemical & Physical Properties
4. Synonyms

Common Name	Avosentan
CAS Number	290815-26-8	Molecular Weight	479.508
Density	1.4±0.1 g/cm3	Boiling Point	575.5±60.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₁N₅O₅S	Melting Point	/
MSDS	/	Flash Point	301.8±32.9 °C

Names

Name	N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
Synonym	More Synonyms

Avosentan BiologicalActivity

Description	Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.IC50 value:Target: ETA receptor
Related Catalog	Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Cardiovascular Disease
References	[1]. Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA. Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol. 2012;3:103. [2]. Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J. Effect of avosentan (SPP-301) in porcine ciliary arteries. Curr Eye Res. 2011 Feb;36(2):118-24. [3]. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group. J Am Soc Nephrol. 2010 Mar;21(3):527-35. [4]. Dieterle W, Hengelage T. Absolute bioavailability and pharmacokinetics of avosentan in man. Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94. [5]. Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.

Description

Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.IC50 value:Target: ETA receptor

Related Catalog

Signaling Pathways >>GPCR/G Protein >>Endothelin ReceptorResearch Areas >>Cardiovascular Disease

References

[1]. Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA. Antidiuretic effects of the endothelin receptor antagonist avosentan. Front Physiol. 2012;3:103.

[2]. Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J. Effect of avosentan (SPP-301) in porcine ciliary arteries. Curr Eye Res. 2011 Feb;36(2):118-24.

[3]. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group. J Am Soc Nephrol. 2010 Mar;21(3):527-35.

[4]. Dieterle W, Hengelage T. Absolute bioavailability and pharmacokinetics of avosentan in man. Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94.

[5]. Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.

Chemical & Physical Properties

Density	1.4±0.1 g/cm3
Boiling Point	575.5±60.0 °C at 760 mmHg
Molecular Formula	C₂₃H₂₁N₅O₅S
Molecular Weight	479.508
Flash Point	301.8±32.9 °C
Exact Mass	479.126343
PSA	133.80000
LogP	0.87
Vapour Pressure	0.0±1.6 mmHg at 25°C
Index of Refraction	1.621
InChIKey	YBWLTKFZAOSWSM-UHFFFAOYSA-N
SMILES	COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C)cn2)nc(-c2ccncc2)nc1OC
Storage condition	2-8℃

Synonyms

Avosentan

UNII-L94KSX715K

2-Pyridinesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-

N-[6-Methoxy-5-(2-methoxyphenoxy)-2-(4-pyridinyl)-4-pyrimidinyl]-5-methyl-2-pyridinesulfonamide

Ro 67-0565

SPP301

Recommended......